Document Detail

Malaria in pregnancy.
Jump to Full Text
MedLine Citation:
PMID:  23350023     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Pregnant women have a higher risk of malaria compared to non-pregnant women. This review provides an update on knowledge acquired since 2000 on P. falciparum and P.vivax infections in pregnancy. Maternal risk factors for malaria in pregnancy (MiP) include low maternal age, low parity, and low gestational age. The main effects of MIP include maternal anaemia, low birth weight (LBW), preterm delivery and increased infant and maternal mortality.P. falciparum infected erythrocytes sequester in the placenta by expressing surface antigens, mainly variant surface antigen (VAR2CSA), that bind to specific receptors, mainly chondroitin sulphate A. In stable transmission settings, the higher malaria risk in primigravidae can be explained by the non-recognition of these surface antigens by the immune system. Recently, placental sequestration has been described also for P.vivax infections. The mechanism of preterm delivery and intrauterine growth retardation is not completely understood, but fever (preterm delivery), anaemia, and high cytokines levels have been implicated.Clinical suspicion of MiP should be confirmed by parasitological diagnosis. The sensitivity of microscopy, with placenta histology as the gold standard, is 60% and 45% for peripheral and placental falciparum infections in African women, respectively. Compared to microscopy, RDTs have a lower sensitivity though when the quality of microscopy is low RDTs may be more reliable. Insecticide treated nets (ITN) and intermittent preventive treatment in pregnancy (IPTp) are recommended for the prevention of MiP in stable transmission settings. ITNs have been shown to reduce malaria infection and adverse pregnancy outcomes by 28-47%. Although resistance is a concern, SP has been shown to be equivalent to MQ and AQ for IPTp. For the treatment of uncomplicated malaria during the first trimester, quinine plus clindamycin for 7 days is the first line treatment and artesunate plus clindamycin for 7 days is indicated if this treatment fails; in the 2(nd) and 3(rd) trimester first line treatment is an artemisinin-based combination therapy (ACT) known to be effective in the region or artesunate and clindamycin for 7 days or quinine and clindamycin. For severe malaria, in the second and third trimester parenteral artesunate is preferred over quinine. In the first trimester, both artesunate and quinine (parenteral) may be considered as options. Nevertheless, treatment should not be delayed and should be started immediately with the most readily available drug.
Ebako Ndip Takem; Umberto D'Alessandro
Related Documents :
12620933 - Temporal regulation of the expression of syncytin (herv-w), maternally imprinted peg10,...
24113293 - Preterm prelabor rupture of membranes (pprom) is not associated with presence of viral ...
9801463 - Levels of corticotrophin-releasing hormone receptor subtype 1 mrna in pregnancy and dur...
Publication Detail:
Type:  Journal Article     Date:  2013-01-02
Journal Detail:
Title:  Mediterranean journal of hematology and infectious diseases     Volume:  5     ISSN:  2035-3006     ISO Abbreviation:  Mediterr J Hematol Infect Dis     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-25     Completed Date:  2013-01-25     Revised Date:  2014-02-20    
Medline Journal Info:
Nlm Unique ID:  101530512     Medline TA:  Mediterr J Hematol Infect Dis     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  e2013010     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Grant Support
MC_UP_A900_1119//Medical Research Council

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Mediterr J Hematol Infect Dis
Journal ID (iso-abbrev): Mediterr J Hematol Infect Dis
Journal ID (publisher-id): Mediterranean Journal of Hematology and Infectious Diseases
ISSN: 2035-3006
Publisher: Università Cattolica del Sacro Cuore
Article Information
Download PDF
Copyright: 2013
Received Day: 28 Month: 9 Year: 2012
Accepted Day: 11 Month: 11 Year: 2012
collection publication date: Year: 2013
Electronic publication date: Day: 02 Month: 1 Year: 2013
Volume: 5 Issue: 1
E-location ID: e2013010
PubMed Id: 23350023
ID: 3552837
DOI: 10.4084/MJHID.2013.010
Publisher Id: mjhid-5-1-e2013010

Malaria in Pregnancy
Ebako Ndip Takem1
Umberto D’Alessandro12
1Medical Research Council Unit, Fajara, The Gambia
2Institute of Tropical Medicine, Antwerp, Belgium
Correspondence: Correspondence to: Prof. Umberto D’Alessandro, Institute of Tropical Medicine, Antwerp, Belgium. E-mail:


Malaria in pregnancy (MiP) is a major public health problem in endemic countries. There is a wealth of evidence showing that the risk of malaria (both infection and clinical disease) is higher in pregnant than in non-pregnant women, possibly due to the immunological, hormonal changes or other factors occurring during pregnancy. Most of the available evidence is on Plasmodium falciparum and P. vivax, though for the latter, there is much less information than for P. falciparum, while little is known on P. ovale and P. malariae, the other two human malaria species. This review will focus on P.falciparum and P. vivax, with the objective of providing an update on the recently acquired knowledge (since the year 2000).


Where transmission is stable and relatively high, mainly in sub-Saharan Africa, adults have acquired immunity against malaria, including pregnant women who, despite the immune tolerance occurring during pregnancy, are able to control but not clear malaria infections. Therefore, in this high risk group, asymptomatic infections are common while clinical malaria is relatively rare. A recent review of studies, carried out in sub-Saharan Africa between 2000 and 2011, reports that malaria prevalence in pregnant women attending antenatal clinics was 29.5% (95%CI: 22.4–36.5) in East and Southern Africa, and 35.1% (95%CI: 28.2–41.9) in West and Central Africa, while the prevalence of placenta malaria was 26.5% (95%CI: 16.7–36.4) in East and Southern Africa, and 38% (95%CI: 28.4–47.6) in West and Central Africa.1 More recently (studies published since 2008), the reported malaria prevalence (by microscopy unless specified otherwise) was lower, reflecting the recent decrease in malaria transmission observed in several African countries211 (Table 1). Most of the prevalence estimates were done by microscopy and they would probably be higher if more sensitive methods like PCR12 or placental histology13 were used. In addition, blood samples were collected at different times during pregnancy, increasing the difficulty of comparing different estimates.

In areas of low, unstable malaria transmission, mainly Asia-Pacific region and South America, pregnant women have a lower acquired immunity and malaria infections are more likely to evolve towards clinical disease. The number of pregnancies occurring in these areas has been estimated at 70.5 million in 2007.14 In the Asia-Pacific region, the median proportion of women with peripheral infection has been estimated at 15.3% and that of placenta malaria at 11%.15 For South and Central America, less data on the burden of malaria in pregnancy is available (Table 2). In Peru, the cumulative incidence of clinical malaria in pregnant women for the period January–August 2004 and 2005 was 43.1% as compared to 31.6% in non-pregnant women.16 This study also suggested that subclinical malaria infections may occur frequently among pregnant women in this region, despite the relatively low transmission, and that passive surveillance, i.e. data collection at health facilities, may underestimate the actual burden of MiP. In Colombia, the prevalence of malaria among parturient women attending the local hospital was 13% when determined by microscopy and 32% by PCR.17 In the same study, the prevalence of placenta malaria was 9% by microscopy and 26% by PCR, while 2% and 13% of cord blood samples were positive by microscopy and PCR, respectively.

Risk Factors

Maternal factors associated with the risk of malaria in pregnancy include maternal age, parity and gestational age. It is well established that younger women (primigravidae and multigravidae), particularly adolescents, are at higher risk of malaria infection than older women,1820 and this is independent of parity.2022 Parity also affects the risk of malaria as primigravidae are at higher risk than multigravidae,1820, 2324 though less in low transmission settings,15 while in epidemic areas, the risk is not affected by parity.25 Most of the available data on malaria relate to the second and third trimesters.12, 19, 2627 The peak of malaria prevalence seems to occur during the second trimester.28 Studies on malaria burden in the first trimester of pregnancy are scarce, but it is believed that the rates are similar to that of the second trimester. However, considering the difficulty of collecting this information (pregnant women start to attend the antenatal clinic after the first trimester), and of determining the gestational age with accuracy, it is unclear whether the risk starts to increase towards the end of the first trimester. Indeed, in Burkina Faso, malaria prevalence was higher during the first as compared to the second and third trimesters.29

Effects of Malaria Infection

The effect of malaria infection during pregnancy will depend on the degree of acquired immunity, which in turn depends on the intensity of transmission.

Maternal effects

Where transmission is stable, such as in most of sub-Saharan Africa, most infections are asymptomatic but increase substantially the risk of anaemia.19,26,3031 This occurs over a background of physiological anaemia of pregnancy due to increased blood volume. Both symptomatic and asymptomatic infections can cause anaemia. Severe anaemia is more often observed in stable transmission settings,3234 and more in primigravidae than in multigravidae.3536 Malaria infections in the first or second trimester of pregnancy increase the risk of anaemia,24,30 though one study reported an increased risk also for infections occurring in the third trimester.30 Preventing malaria infection by intermittent preventive treatment during pregnancy (IPTp) reduces the risk of anaemia.27,3738

Where malaria transmission is unstable, malaria can cause maternal anaemia,18,35,3940 more in primigravidae than in multigravidae and for falciparum infections more than for vivax infections.18,35 Nevertheless, severe anaemia is less common in these settings.39,41

In places where malaria transmission is stable, little is known on the importance of malaria infection as a cause of miscarriage. Where malaria transmission is unstable, malaria as a cause of miscarriage seems more common, as the majority of infections evolve towards a clinical attack with fever, which may by itself determine miscarriage. Indeed, non malarial fevers also independently increase the risk of miscarriage.18,42 Nevertheless, asymptomatic infections, i.e. slide confirmed malaria with no history of fever in the previous 48 hours and temperature <37.5 °C, was also associated with miscarriage.7

Maternal mortality associated to malaria is probably under-reported. Malaria was an important cause of maternal death in some studies,4345 while in others it was not as frequent.46 The substantial reduction in maternal mortality observed in Thailand after the implementation of early detection and treatment of malaria suggests that malaria is an important contributor to maternal mortality.47 When not a direct cause of death (severe malaria),47 malaria in pregnancy is often reported as co-morbidity, e.g. with eclampsia, in conditions associated with maternal mortality.44,48

Perinatal effects

Malaria increases the risk of low birth weight (LBW),19,23,30,4951 particularly in primigravidae, and this risk seems to be higher for infections in first or second trimester,2324,30,49 though in one study this was true also for infections occurring late in pregnancy.49 In high malaria transmission settings, such an effect is due to intrauterine growth retardation (IUGR) rather than pre-term delivery, as most infections are asymptomatic. A meta-analysis of 32 cross-sectional data in Africa, showed malaria prevention in pregnancy is associated with 21% (95% CI= 14–27) reduction in LBW.52

In unstable transmission settings, preterm deliveries, still births and neonatal deaths have been associated with malaria.18P.vivax infections are also associated with LBW, and this effect appears to be similar in all pregnancies. In women with a single infection of P.vivax or P.falciparum detected and treated in the first trimester, no significant effect on gestation or birth weight was observed compared to women who also attended in the first trimester but who never had malaria detected in pregnancy.42

New born and infant effects

Fewer studies on malaria in pregnant women have evaluated infant outcomes. Congenital malaria can occur in the neonatal period and can contribute to infant morbidity and mortality.53 Placenta malaria, especially active infection, has been linked to neonatal and infant mortality.53 A recent study in The Gambia has showed that malaria infection during pregnancy influences infant’s growth, independently of LBW.54 It also increases the risk of infant’s death and perinatal mortality, by causing LBW.39,53,55 This is confirmed by the reduction neonatal mortality, up to 60%, observed after the implementation of preventive interventions targeted to pregnant women, e.g. intermittent preventive treatment.5657 In primi- and secundigravidae, malaria prevention with IPTp or insecticide-treated bed nets was significantly associated with a 18% decreased risk of neonatal mortality.52

Later childhood, adolescence and adulthood effects

The long term effects of malaria in pregnancy have not been studied. However, malaria causes IUGR leading to LBW, which may be related to diseases occurring during adulthood, including some cancers and the metabolic syndrome.58


Pregnant women are at higher risk of contracting malaria than non-pregnant women. This increased susceptibility can be explained by the immunological changes induced by pregnancy, by hormonal factors,59 and by the higher attractiveness of pregnant women to mosquitoes.6061 In addition, P. falciparum -infected erythrocytes in pregnant women bind to specific receptors, i.e. chondroitin sulphate A (CSA), and sequester in the placenta.6263 They rarely bind to the other two commonly described receptors in non-pregnant individuals, i.e. CD36 and the intracellular adhesion molecule (ICAM-1). In pregnancy, the parasite antigens expressed on infected erythrocytes are collectively known as variant surface antigen-pregnancy associated malaria (VSAPAM). They are different from those expressed in non-pregnant individuals and in stable transmission settings are not recognised by the immune system, explaining the higher risk in primigravidae.64 The binding of the variant surface antigen (VAR2CSA) with chondroitin sulphate A has been implicated in the pathology of falciparum malaria in pregnancy.6568 The VAR2CSA belongs to the family of the erythrocyte membrane protein (PfEMP1), is encoded by the var2csa gene and its expression has been described in pregnant women with falciparum malaria.69 Levels of anti-VAR2CSA specific IgGs increase with parity, cannot be found in men and are associated with a favourable pregnancy outcome 6466 so that the malaria risk decreases with increasing parity. Besides the antibody responses to VSAPAM, cytokine responses such as Th1, Th2, interleukins, TNF and regulators, IFN gamma,7072 and monocytes73 have been observed in pregnant women with malaria. Rosetting, a phenomenon consisting of parasite-free erythrocytes surrounding parasite-infected erythrocytes and commonly observed in non-pregnant individuals, has been implicated in the pathogenesis of severe malaria7475 but is uncommon in pregnant women with falciparum malaria.76

The sequestration of P. vivax in the placenta, though until recently thought not to occur, has been described,7778 with the involvement of ICAM-1 and CSA as receptors.

The effects of hormonal changes on pregnancy associated malaria have been described in few studies and are subject to debate. Increased cortisol levels have been associated with increased risk of malaria in pregnant women.79

The increased attractiveness of pregnant women to mosquitoes may be explained by physiological and behavioural changes occurring during pregnancy. Physiological changes include increased exhaled breath and increased abdominal temperature that may render pregnant women more easily detectable by mosquitoes. Behavioural changes are represented by the fact that pregnant women urinate twice as frequently as non-pregnant women, resulting in an increased exposure to mosquito bites at night because they have to leave the protection of their bed nets.6061

Malaria-associated placental changes have been described for stable72,80 and unstable transmission settings.73,81 They include presence of parasites, inflammatory changes and hemozoin (pigment) deposition. Placental changes have been characterised into four levels, i.e. acute (parasites present, malaria pigment absent), chronic (parasites and malaria pigment present), past infection (no parasite but pigment present) and no infection (both parasites and malaria pigment absent).82 Recently, a 2-parameter grading system, distinguishing between inflammation and pigment deposition, has been proposed as it correlates with pregnancy outcomes, in both a stable transmission setting in Tanzania, and an unstable setting in Thailand.73

It is unclear what the mechanism at the basis of malaria-related preterm delivery is, though fever, anaemia, and high levels of TNF alpha or interleukin 10 have been identified as important risk factors.18,8384

LBW due to IUGR is associated with maternal anaemia,83,85 and elevated levels of cytokines.70 Although the exact mechanism has not been elucidated, it appears to be due to chronic infections that cause reduced foetal circulation and placental insufficiency.86 Placental endocrine changes related to falciparum infection have been suggested as another possible mechanism leading to IUGR.87

P.vivax is different from P. falciparum as it infects immature erythrocytes (reticulocytes), limiting the parasite densities. In addition, it can relapse during pregnancy due to the activation of liver hypnozoites. Vivax parasites do not frequently express variant surface antigens, at the basis of placenta sequestration, so that this does not occur frequently.81 Therefore, P. vivax probably affects birth weight, and increases the risk of miscarriage and preterm birth through a systemic rather than a local effect. Nevertheless, the mechanisms at the basis of these observations are not completely understood.

Clinical Presentation

The diagnosis of malaria in pregnancy is essential to prevent its deleterious effects to the mother and the foetus. Unfortunately, the clinical signs of malaria in pregnant women are usually non specific, and where transmission is stable, most infections are asymptomatic. Therefore, suspected malaria cases should be confirmed by parasitological diagnosis,88 usually by microscopy and/or rapid diagnostic tests. Nevertheless, other methods such as PCR and placental histology can be also used, though the latter can be done only after delivery so that it cannot be used for the management of infections occurring during pregnancy.

Microscopy is one of the most widely used methods for diagnosing malaria, including during pregnancy. It has some advantages such as the possibility of determining the parasite density and species. However, its major disadvantage, besides the need of a regular power supply, is its sensitivity, which cannot go below 10–15 parasites per μl. Therefore, a substantial proportion of infected pregnant women would not be detected because of extremely low parasite densities or of parasites sequestered in the placenta, though both conditions have deleterious effects on the mother’s and her offspring’s health.

Several studies have investigated the use of microscopy for the diagnosis of MiP in stable malaria transmission settings in Africa.8991 When taking placenta histology as the reference test, the sensitivity of peripheral blood microscopy for _P. falciparum infections (4 studies) was 60% (95% CI=50–69) and that of placental microscopy 45% (95% CI=34–56).13

In settings with unstable malaria transmission, there are few studies on the sensitivity of microscopy on peripheral blood collected during pregnancy.13

Rapid diagnostic tests (RDT), detecting circulating malaria antigens, can also be used. Generally, the sensitivity of RDTs for the diagnosis of malaria in pregnancy is lower than that of microscopy. However, the time needed for the diagnosis is shorter than for microscopy and the training required for their use is minimal. Although RDT can detect malaria antigens, they cannot estimate the parasite density. The sensitivity of RDT on peripheral blood using peripheral microscopy as a reference test is estimated at 81% (95% CI= 55–95), and the sensitivity of RDT on placental blood was 81% (95% CI= 62–92) using placental microscopy as the reference.13

PCR, which detects parasite DNA, can also be used for the diagnosis of malaria infection but is not readily available in health facilities. In stable transmission settings, the sensitivity of PCR was >80% when using microscopy as the reference.13 PCR sensitivity has not been estimated against placental histology as reference test.

Severe malaria

Severe malaria in pregnancy is more common in unstable transmission settings because of the lower immunity pregnant women have. Generally, women in the second and third trimesters of pregnancy are at a higher risk of developing severe malaria compared to non-pregnant adults. In low transmission settings, severe malaria in pregnancy is usually associated with pulmonary oedema, hypoglycaemia and severe anaemia. Mortality in pregnant women with severe malaria and treated with either artesunate and quinine varied between 9% and 12%.92

Prevention and Treatment

The most widely used interventions to prevent malaria in pregnancy are insecticide-treated bed nets (ITN), including Long-Lasting Insecticidal Nets (LLINs), and intermittent preventive treatment in pregnancy (IPTp).

While ITNs have shown a substantial reduction in malaria morbidity and mortality in children,9394,95,96 in pregnant women, it has been associated with a decrease in maternal parasitaemia (38%), anaemia (41%) and LBW (28%),97 and 47% reduction in maternal anaemia.98 In one study, there was no evidence of a reduction in anaemia and parasitaemia.99

IPTp is the administration of therapeutic doses of an antimalarial, currently sulfadoxine-pyrimethamine (SP), at least twice during pregnancy, in the second and third trimester, irrespective of the presence of a malaria infection. The WHO recommends its use and many sub-Saharan African countries have included it in their malaria control program. In stable transmission settings, many trials have shown that SP given as IPTp is efficacious in preventing the adverse consequences of malaria during pregnancy (Table 3).100104 However, SP resistance represents a major threat. A study in Benin has showed that, despite the presence of molecular markers of resistance, SP remained efficacious.105 This has been confirmed by a review reporting that IPTp with SP is effective up to a certain level of SP resistance.106 Nevertheless, finding an alternative to SP for IPTp is important. Adding amodiaquine to SP was efficacious but not better than SP alone.107 Mefloquine (MQ), thanks to its long elimination half-life, could be a good alternative to SP as it would provide a long post-treatment prophylactic period. Indeed, a trial in Benin showed that for IPTp MQ was as good as SP in preventing LBW. MQ was more efficacious than SP in preventing placental malaria, clinical malaria and maternal anaemia at delivery. However, MQ was less well tolerated than SP, potentially compromising its large scale use as IPTp.108109

There is no evidence that one of the methods is better than the other110 and the combined use appears to be better than individual use.

A different approach is systematic screening for malaria infections at regular intervals and treatment of the positive women, which may be more appropriate in settings where malaria transmission is low and the risk of infection between antenatal visits is also low. It has already be shown to have similar protective efficacy than IPTp but additional trials for a more thorough evaluation of this intervention are probably needed.26 Due to drug resistant malaria, it has been the only form of malaria control on the Thai-Burmese border for more than 20 years, impacting significantly on maternal mortality rates.47

In future, vaccines specifically designed to prevent MiP may become available; VAR2CSA, in the early stages of development, seems the most promising candidate.111116 However, there are still several uncertainties, including the number of antigenic variants to be combined for an optimal response, the timing of the vaccine, e.g. during pregnancy or at puberty, whether only first pregnancies should be targeted, and the length of follow up for children born to vaccinated mothers.111112,117


It is recommended that pregnant women with malaria are treated after parasitological confirmation of the diagnosis, reducing the unnecessary exposure to antimalarials of both the mother and the foetus.

First trimester

Clinical trials on the safety and efficacy of antimalarials in pregnancy usually exclude women in the first trimester of pregnancy so that the evidence is based on observational studies (Table 4). Artemisinin derivatives were relatively safe (n=1937) in the first trimester of pregnancy42,118119 and the cumulative failure rate reported in only one study was 6.6% across all trimesters (n=461).118 No major adverse event was observed in 377 women with known pregnancy outcome and exposed to artemisinins in the first trimester.42,119121 However, only 1 study120 out of 4, was a randomised controlled trial though the treatment was given during a mass campaign and the exposure was thus inadvertent; the birth weight of newborns delivered by women exposed to artesunate during the first trimester was similar to that of the other pregnant women. According to recommendations,88 chloroquine, quinine, clindamycin and proguanil can be considered safe in the first trimester.

In case of uncomplicated malaria in the first trimester, a combination of quinine + clindamycin for 7 days is recommended.

In case of severe malaria, parenteral antimalarials are recommended.88 In the first trimester, the risk of hypoglycaemia is lower and the uncertainties on the safety of the artemisinins derivatives are greater. Nevertheless, considering that treatment should not be delayed and that artesunate reduces the risk of death, both artesunate and quinine (parenteral) may be considered as options. Treatment should be started immediately with the most readily available drug.90

Second and third trimesters

There is more experience on the use of artemisinin derivatives in the second and third trimesters of pregnancy. Evidence is available from both trials122127 and observational studies128131 involving pregnant women (Table 4). Data available indicate that ACTs are relatively safe for the foetus when taken after the first trimester of pregnancy. A recent review of treatment studies carried out in pregnant women from 1998–2009, reported a parasitological failure >5% in 3 out of 11 trials.132 In the second trimester, ACTs that are known to be effective in the area, or 7 days artesunate+ clindamycin, or 7 days quinine+ clindamycin are recommended for uncomplicated malaria.88 In case of severe malaria, parenteral artesunate is preferable because it saves the life of the mother. Several studies have shown that the kinetics of artemisinins derivatives, most specifically of the active metabolite dihydroartemisinin, is modified during pregnancy.133134

Amodiaquine (AQ) has been shown to be efficacious in pregnant women with falciparum malaria in Ghana and Tanzania.122,125 Day 28 parasitological failure rates were 3% for AQ monotherapy,122 0–1% for the combination AQ+SP,122,125 and 4.5% for the combination AS+AQ.125 It was relatively safe and well tolerated and associated with some minor side effects (nausea, weakness, dizziness). Blood dyscrasias were not a problem associated with its use. A pharmacokinetics study on AQ for treatment of P.vivax in pregnancy conducted in Thailand indicates the doses are similar to that of non-pregnant adults.131,135

There are fewer reports on the efficacy and safety of mefloquine (MQ) for MiP. High cure rates have been reported in Thailand, for the combination of MQ+AS (cure rate of 98.2% at day 63).126 One study reported minor side effects.109 However, there are concerns about still births and neuropsychiatric disorders. There are currently some ongoing clinical studies which will provide useful data on the safety, efficacy and pharmacokinetics of MQ in pregnant women (Table 5). The combination AS+ MQ is being evaluated in studies in Africa and Asia (NCT00852423, NCT00701961, NCT01054248, CTRI/2009/091/001055TEMP, NCT01054248).

In Uganda, in an area of relatively high transmission and hence with pregnant women having some acquired immunity, artemether-Lumefantrine (AL) was efficacious, with cure rates >95%.136137 However, in Thailand the cure rate at day 42 was only 82%,138 possibly due to the low day 7 lumefantrine concentrations. AL was safe and well tolerated.136138 As for other antimalarial treatments, pharmacokinetics may be altered during pregnancy, with plasma concentrations lower than expected.129,139 AL is currently being evaluated in Thailand and in four sites in sub-Saharan Africa (NCT01054248, NCT00852423).

Dihydroartemisinin piperaquine (DHAPQ) was highly effective in women with multiple recrudescent infections on the Thai-Burmese border.140 DHAPQ is used in the Western Pacific for malaria in pregnant women.141 DHA-PQ is currently being evaluated in 3 studies in Africa and Asia (NCT00852423, NCT01054248, NCT01231113). Cure rates and PK are reassuring.

In Thailand, atovaquone-proguanil in combination with artesunate (AAP) was associated with high cure rates (>95%) and was relatively safe,123,142 though the sample size was small. In Thailand, plasma concentrations of AAP were lower in pregnant than in non pregnant women.143


This review shows that although the deleterious effects of MiP to both the mother and the child are well documented, the mechanisms involved are still relatively unknown, particularly where transmission is low and unstable. The diagnosis of MiP is challenging, as peripheral microscopy will miss a large proportion of infected women with parasites sequestered in the placenta. MiP can be prevented by currently available control methods, i.e. ITNs and IPTp, but the challenge is attaining a high coverage, particularly for women with the highest risk such as adolescent primigravidae. It is still unclear what would be the alternative to SP for the IPTp.

The burden of P. vivax MiP, which is substantial in the Asia-Pacific region and in South America has been relatively neglected. It is generally believed that vivax infections are milder than falciparum ones, but this is based on few studies. There is also the need of having more sensitive diagnostic methods for vivax infections, as it would help improving early diagnosis and appropriate management. Finally, information of the safety and efficacy of antimalarials during pregnancy is growing, though this is true mainly for the second and third trimester. For the first trimester, treatment options are still extremely limited and evidence is mainly based on pharmacovigilance data on accidental exposures.


fn1-mjhid-5-1-e2013010Competing interests: The authors have declared that no competing interests exist.

1. Chico RM,Mayaud P,Ariti C,Mabey D,Ronsmans C,Chandramohan D. Prevalence of malaria and sexually transmitted and reproductive tract infections in pregnancy in sub-Saharan Africa: a systematic reviewJAMAYear: 201230719207986 22665107
2. Teklehaimanot HD,Teklehaimanot A,Kiszewski A,Rampao HS,Sachs JD. Malaria in Sao Tome principe: on the brink of elimination after three years of effective antimalarial measuresAm J Trop Med HygYear: 20098011334019141851
3. Lee PW,Liu CT,Rampao HS,do Rosario VE,Shaio MF. Pre-elimination of malaria on the island of PrincipeMalar JYear: 2010926 282360720089158
4. Beiersmann C,Bountogo M,Tiendrebeogo J,De Allegri M,Louis VR,Coulibaly B,Ye M,Mueller O. Falciparum malaria in young children of rural Burkina Faso: comparison of survey data in 1999 with 2009Malar JYear: 201110296 320018521989335
5. Bouyou-Akotet MK,Mawili-Mboumba DP,Kendjo E,Mabika-Mamfoumbi M,Ngoungou EB,Dzeing-Ella A,Pemba-Mihindou M,Ibinga E,Efame-Eya E,Planche T,Kremsner PG,Kombila M. Evidence of decline of malaria in the general hospital of Libreville, Gabon from 2000 to 2008Malar JYear: 20098300 280638020017905
6. Otten M,Aregawi M,Were W,Karema C,Medin A,Bekele W,Jima D,Gausi K,Komatsu R,Korenromp E,Low-Beer D,Grabowsky M. Initial evidence of reduction of malaria cases and deaths in Rwanda and Ethiopia due to rapid scale-up of malaria prevention and treatmentMalar JYear: 2009814 265350319144183
7. Graves PM,Osgood DE,Thomson MC,Sereke K,Araia A,Zerom M,Ceccato P,Bell M,Del Corral J,Ghebreselassie S,Brantly EP,Ghebremeskel T. Effectiveness of malaria control during changing climate conditions in Eritrea, 1998–2003Trop Med Int HealthYear: 200813221828 349940718304268
8. Bhattarai A,Ali AS,Kachur SP,Martensson A,Abbas AK,Khatib R,Al-Mafazy AW,Ramsan M,Rotllant G,Gerstenmaier JF,Molteni F,Abdulla S,Montgomery SM,Kaneko A,Bjorkman A. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in ZanzibarPLoS MedYear: 2007411e309 206248117988171
9. O’Meara WP,Bejon P,Mwangi TW,Okiro EA,Peshu N,Snow RW,Newton CR,Marsh K. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, KenyaLancetYear: 20083729649155562 18984188
10. Ceesay SJ,Casals-Pascual C,Erskine J,Anya SE,Duah NO,Fulford AJ,Sesay SS,Abubakar I,Dunyo S,Sey O,Palmer A,Fofana M,Corrah T,Bojang KA,Whittle HC,Greenwood BM,Conway DJ. Changes in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysisLancetYear: 20083729649154554 18984187
11. Ceesay SJ,Casals-Pascual C,Nwakanma DC,Walther M,Gomez-Escobar N,Fulford AJC,Takem EN,Nogaro S,Bojang KA,Corrah T,Jaye MC,Taal MA,Sonko AAJ,Conway DJ. Continued Decline of Malaria in The Gambia with Implications for EliminationPLoS ONEYear: 201058e12242 292360520805878
12. Rantala AM,Taylor SM,Trottman PA,Luntamo M,Mbewe B,Maleta K,Kulmala T,Ashorn P,Meshnick SR. Comparison of real-time PCR and microscopy for malaria parasite detection in Malawian pregnant womenMalar JYear: 20109269 298456720925928
13. Kattenberg JH,Ochodo EA,Boer KR,Schallig HD,Mens PF,Leeflang MM. Systematic review and meta-analysis: rapid diagnostic tests versus placental histology, microscopy and PCR for malaria in pregnant womenMalar JYear: 201110321 322886822035448
14. Dellicour S,Tatem AJ,Guerra CA,Snow RW,ter Kuile FO. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic studyPLoS MedYear: 201071e1000221 281115020126256
15. Rijken MJ,McGready R,Boel ME,Poespoprodjo R,Singh N,Syafruddin D,Rogerson S,Nosten F. Malaria in pregnancy in the Asia-Pacific regionLancet Infect DisYear: 20121217588 22192132
16. Parekh FK,Hernandez JN,Krogstad DJ,Casapia WM,Branch OH. Prevalence and risk of Plasmodium falciparum and P. vivax malaria among pregnant women living in the hypoendemic communities of the Peruvian AmazonAm J Trop Med HygYear: 2007773451717827359
17. Campos IM,Uribe ML,Cuesta C,Franco-Gallego A,Carmona-Fonseca J,Maestre A. Diagnosis of gestational, congenital, and placental malaria in Colombia: comparison of the efficacy of microscopy, nested polymerase chain reaction, and histopathologyAm J Trop Med HygYear: 201184692935 311037021633030
18. Poespoprodjo JR,Fobia W,Kenangalem E,Lampah DA,Warikar N,Seal A,McGready R,Sugiarto P,Tjitra E,Anstey NM,Price RN. Adverse pregnancy outcomes in an area where multidrug-resistant plasmodium vivax and Plasmodium falciparum infections are endemicClin Infect DisYear: 2008469137481 287510018419439
19. Ayoola OO,Whatmore A,Balogun WO,Jarrett OO,Cruickshank JK,Clayton PE. Maternal malaria status and metabolic profiles in pregnancy and in cord blood: relationships with birth size in Nigerian infantsMalar JYear: 20121175 332516222429464
20. Hamer DH,Singh MP,Wylie BJ,Yeboah-Antwi K,Tuchman J,Desai M,Udhayakumar V,Gupta P,Brooks MI,Shukla MM,Awasthy K,Sabin L,MacLeod WB,Dash AP,Singh N. Burden of malaria in pregnancy in Jharkhand State, IndiaMalar JYear: 20098210 274470219728882
21. Espinoza E,Hidalgo L,Chedraui P. The effect of malarial infection on maternal-fetal outcome in EcuadorJ Matern Fetal Neonatal MedYear: 20051821015 16203594
22. Walker-Abbey A,Djokam RR,Eno A,Leke RF,Titanji VP,Fogako J,Sama G,Thuita LH,Beardslee E,Snounou G,Zhou A,Taylor DW. Malaria in pregnant Cameroonian women: the effect of age and gravidity on submicroscopic and mixed-species infections and multiple parasite genotypesAm J Trop Med HygYear: 20057232293515772312
23. Valea I,Tinto H,Drabo MK,Huybregts L,Sorgho H,Ouedraogo JB,Guiguemde RT,van Geertruyden JP,Kolsteren P,D’Alessandro U. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina FasoMalar JYear: 20121171 333839622433778
24. Kalilani L,Mofolo I,Chaponda M,Rogerson SJ,Meshnick SR. The effect of timing and frequency of Plasmodium falciparum infection during pregnancy on the risk of low birth weight and maternal anemiaTrans R Soc Trop Med HygYear: 2010104641622 20207387
25. Newman RD,Hailemariam A,Jimma D,Degifie A,Kebede D,Rietveld AE,Nahlen BL,Barnwell JW,Steketee RW,Parise ME. Burden of malaria during pregnancy in areas of stable and unstable transmission in Ethiopia during a nonepidemic yearJ Infect DisYear: 200318711176572 12751034
26. Tagbor H,Bruce J,Agbo M,Greenwood B,Chandramohan D. Intermittent screening and treatment versus intermittent preventive treatment of malaria in pregnancy: a randomized controlled non-inferiority trialPLoS ONEYear: 2010512e14425 301099921203389
27. Wilson NO,Ceesay FK,Obed SA,Adjei AA,Gyasi RK,Rodney P,Ndjakani Y,Anderson WA,Lucchi NW,Stiles JK. Intermittent preventive treatment with sulfadoxine-pyrimethamine against malaria and anemia in pregnant womenAm J Trop Med HygYear: 20118511221 312233721734118
28. Agbor-Enoh ST,Achur RN,Valiyaveettil M,Leke R,Taylor DW,Gowda DC. Chondroitin sulfate proteoglycan expression and binding of Plasmodium falciparum-infected erythrocytes in the human placenta during pregnancyInfect ImmunYear: 2003715245561 15326912704116
29. Coulibaly SO,Gies S,D’Alessandro U. Malaria burden among pregnant women living in the rural district of Boromo, Burkina FasoAm J Trop Med HygYear: 2007776 Suppl566018165475
30. Huynh BT,Fievet N,Gbaguidi G,Dechavanne S,Borgella S,Guezo-Mevo B,Massougbodji A,Ndam NT,Deloron P,Cot M. Influence of the timing of malaria infection during pregnancy on birth weight and on maternal anemia in BeninAm J Trop Med HygYear: 201185221420 314481521813837
31. Bouyou-Akotet MK,Ionete-Collard DE,Mabika-Manfoumbi M,Kendjo E,Matsiegui PB,Mavoungou E,Kombila M. Prevalence of Plasmodium falciparum infection in pregnant women in GabonMalar JYear: 2003218 18385612919637
32. van Eijk AM,Ayisi JG,Slutsker L,Ter Kuile FO,Rosen DH,Otieno JA,Shi YP,Kager PA,Steketee RW,Nahlen BL. Effect of haematinic supplementation and malaria prevention on maternal anaemia and malaria in western KenyaTrop Med Int HealthYear: 200712334252 349940717313505
33. Tarimo SD. Appraisal on the prevalence of malaria and anaemia in pregnancy and factors influencing uptake of intermittent preventive therapy with sulfadoxine-pyrimethamine in Kibaha district, TanzaniaEast Afr J Public HealthYear: 20074280318085136
34. Achidi EA,Kuoh AJ,Minang JT,Ngum B,Achimbom BM,Motaze SC,Ahmadou MJ. Troye-Blomberg M, Malaria infection in pregnancy and its effects on haemoglobin levels in women from a malaria endemic area of Fako Division, South West Province, CameroonJ Obstet GynaecolYear: 200525323540 349837316147724
35. Guyatt HL,Snow RW. The epidemiology and burden of Plasmodium falciparum-related anemia among pregnant women in sub-Saharan AfricaAm J Trop Med HygYear: 2001641–2 Suppl364411425176
36. Shulman CE,Marshall T,Dorman EK,Bulmer JN,Cutts F,Peshu N,Marsh K. Malaria in pregnancy: adverse effects on haemoglobin levels and birthweight in primigravidae and multigravidaeTrop Med Int HealthYear: 20016107708 11679125
37. Gies S,Coulibaly SO,Ouattara FT,D’Alessandro U. Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weightTrop Med Int HealthYear: 200914217482 349940719171009
38. Kayentao K,Kodio M,Newman RD,Maiga H,Doumtabe D,Ongoiba A,Coulibaly D,Keita AS,Maiga B,Mungai M,Parise ME,Doumbo O. Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in MaliJ Infect DisYear: 2005191110916 15593011
39. Luxemburger C,McGready R,Kham A,Morison L,Cho T,Chongsuphajaisiddhi T,White NJ,Nosten F. Effects of malaria during pregnancy on infant mortality in an area of low malaria transmissionAm J EpidemiolYear: 2001154545965 11532788
40. Rodriguez-Morales AJ,Sanchez E,Vargas M,Piccolo C,Colina R,Arria M,Franco-Paredes C. Pregnancy outcomes associated with Plasmodium vivax malaria in northeastern VenezuelaAm J Trop Med HygYear: 2006745755716687675
41. O’Donnell A,Raiko A,Clegg JB,Weatherall DJ,Allen SJ. Southeast Asian ovalocytosis and pregnancy in a malaria-endemic region of Papua New GuineaAm J Trop Med HygYear: 2007764631317426161
42. McGready R,Lee SJ,Wiladphaingern J,Ashley EA,Rijken MJ,Boel M,Simpson JA,Paw MK,Pimanpanarak M,Mu O,Singhasivanon P,White NJ,Nosten FH. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based studyLancet Infect DisYear: 201212538896 22169409
43. Romagosa C,Ordi J,Saute F,Quinto L,Machungo F,Ismail MR,Carrilho C,Osman N,Alonso PL,Menendez C. Seasonal variations in maternal mortality in Maputo, Mozambique: the role of malariaTrop Med Int HealthYear: 200712162717207149
44. Anya SE. Seasonal variation in the risk and causes of maternal death in the Gambia: malaria appears to be an important factorAm J Trop Med HygYear: 2004705510315155982
45. Ali AA,Okud A,Khojali A,Adam I. High incidence of obstetric complications in Kassala Hospital, Eastern SudanJ Obstet GynaecolYear: 20123221489 349837322296425
46. Somigliana E,Sabino A,Schrettenbrunner C,Nkurunziza R,Okello E,Manenti F. A comprehensive and integrated project to improve reproductive health at Oyam district, northern Uganda: insights from maternal death review at the district hospitalArch Gynecol ObstetYear: 201128336459 21113718
47. McGready R,Boel M,Rijken MJ,Ashley EA,Cho T,Moo O,Paw MK,Pimanpanarak M,Hkirijareon L,Carrara VI,Lwin KM,Phyo AP,Turner C,Chu CS,van Vugt M,Price RN,Luxemburger C,ter Kuile FO,Tan SO,Proux S,Singhasivanon P,White NJ,Nosten FH. Effect of early detection and treatment on malaria related maternal mortality on the north-western border of Thailand 1986–2010PLoS ONEYear: 201277e40244 339983422815732
48. Adam I,Elhassan EM,Mohmmed AA,Salih MM,Elbashir MI. Malaria and pre-eclampsia in an area with unstable malaria transmission in Central SudanMalar JYear: 201110258 322426121899731
49. Cottrell G,Mary JY,Barro D,Cot M. The importance of the period of malarial infection during pregnancy on birth weight in tropical AfricaAm J Trop Med HygYear: 20077658495417488903
50. Kassam SN,Nesbitt S,Hunt LP,Oster N,Soothill P,Sergi C. Pregnancy outcomes in women with or without placental malaria infectionInt J Gynaecol ObstetYear: 200693322532 346527216626713
51. Akum AE,Kuoh AJ,Minang JT,Achimbom BM,Ahmadou MJ,Troye-Blomberg M. The effect of maternal, umbilical cord and placental malaria parasitaemia on the birthweight of newborns from South-western CameroonActa PaediatrYear: 200594791723 16188815
52. Eisele TP,Larsen DA,Anglewicz PA,Keating J,Yukich J,Bennett A,Hutchinson P,Steketee RW. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in AfricaLancet Infect DisYear: 2012
53. Bardaji A,Sigauque B,Sanz S,Maixenchs M,Ordi J,Aponte JJ,Mabunda S,Alonso PL,Menendez C. Impact of malaria at the end of pregnancy on infant mortality and morbidityJ Infect DisYear: 201120356919 307127621199881
54. Walther B,Miles DJ,Crozier S,Waight P,Palmero MS,Ojuola O,Touray E,van der Sande M,Whittle H,Rowland-Jones S,Flanagan KL. Placental malaria is associated with reduced early life weight development of affected children independent of low birth weightMalar JYear: 2010916 284160920074331
55. Diamond-Smith N,Singh N,Gupta RK,Dash A,Thimasarn K,Campbell OM,Chandramohan D. Estimating the burden of malaria in pregnancy: a case study from rural Madhya Pradesh, IndiaMalar JYear: 2009824 264755119210797
56. Titaley CR,Dibley MJ,Roberts CL,Agho K. Combined iron/folic acid supplements and malaria prophylaxis reduce neonatal mortality in 19 sub-Saharan African countriesAm J Clin NutrYear: 201092123543 20504976
57. Menendez C,Bardaji A,Sigauque B,Sanz S,Aponte JJ,Mabunda S,Alonso PL. Malaria prevention with IPTp during pregnancy reduces neonatal mortalityPLoS ONEYear: 201052e943820195472
58. Christensen DL,Kapur A,Bygbjerg IC. Physiological adaption to maternal malaria and other adverse exposure: low birth weight, functional capacity, and possible metabolic disease in adult lifeInt J Gynaecol ObstetYear: 2011115Suppl 1S16922099434
59. Rogerson SJ,Hviid L,Duffy PE,Leke RF,Taylor DW. Malaria in pregnancy: pathogenesis and immunityLancet Infect DisYear: 20077210517 17251081
60. Lindsay S,Ansell J,Selman C,Cox V,Hamilton K,Walraven G. Effect of pregnancy on exposure to malaria mosquitoesLancetYear: 200035592191972 10859048
61. Ansell J,Hamilton KA,Pinder M,Walraven GE,Lindsay SW. Short-range attractiveness of pregnant women to Anopheles gambiae mosquitoesTrans R Soc Trop Med HygYear: 20029621136 12055794
62. Cserti CM,Dzik WH. The ABO blood group system and Plasmodium falciparum malariaBloodYear: 2007110722508 17502454
63. Fairhurst RM,Wellems TE. Modulation of malaria virulence by determinants of Plasmodium falciparum erythrocyte membrane protein-1 displayCurr Opin HematolYear: 200613312430 16567953
64. Staalsoe T,Shulman CE,Bulmer JN,Kawuondo K,Marsh K,Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malariaLancetYear: 200436394052839 14751701
65. Salanti A,Dahlback M,Turner L,Nielsen MA,Barfod L,Magistrado P,Jensen AT,Lavstsen T,Ofori MF,Marsh K,Hviid L,Theander TG. Evidence for the involvement of VAR2CSA in pregnancy-associated malariaJ Exp MedYear: 200420091197203 221185715520249
66. Tuikue Ndam NG,Salanti A,Bertin G,Dahlback M,Fievet N,Turner L,Gaye A,Theander T,Deloron P. High level of var2csa transcription by Plasmodium falciparum isolated from the placentaJ Infect DisYear: 200519223315 15962229
67. Ofori MF,Staalsoe T,Bam V,Lundquist M,David KP,Browne EN,Akanmori BD,Hviid L. Expression of variant surface antigens by Plasmodium falciparum parasites in the peripheral blood of clinically immune pregnant women indicates ongoing placental infectionInfect ImmunYear: 200371315846 14887512595482
68. Duffy PE,Fried M. Plasmodium falciparum adhesion in the placentaCurr Opin MicrobiolYear: 2003643716 12941407
69. Sander AF,Salanti A,Lavstsen T,Nielsen MA,Theander TG,Leke RG,Lo YY,Bobbili N,Arnot DE,Taylor DW. Positive selection of Plasmodium falciparum parasites with multiple var2csa-type PfEMP1 genes during the course of infection in pregnant womenJ Infect DisYear: 201120311167985 309679521592998
70. Thevenon AD,Zhou JA,Megnekou R,Ako S,Leke RG,Taylor DW. Elevated levels of soluble TNF receptors 1 and 2 correlate with Plasmodium falciparum parasitemia in pregnant women: potential markers for malaria-associated inflammationJ ImmunolYear: 201018511711522 298808620980627
71. Achidi EA,Apinjoh TO,Titanji VP. Malaria parasitemia and systemic cytokine bias in pregnancyInt J Gynaecol ObstetYear: 20079711520 346527217331514
72. Sarr D,Aldebert D,Marrama L,Frealle E,Gaye A,Brahim HO,Niang M,Dangou JM,Mercereau-Puijalon O,Lehesran JY,Jambou R. Chronic infection during placental malaria is associated with up-regulation of cycloxygenase-2Malar JYear: 2010945 283190420144201
73. Parekh FK,Davison BB,Gamboa D,Hernandez J,Branch OH. Placental histopathologic changes associated with subclinical malaria infection and its impact on the fetal environmentAm J Trop Med HygYear: 201083597380 296395521036823
74. Cockburn IA,Mackinnon MJ. O’Donnell A, Allen SJ, Moulds JM, Baisor M, Bockarie M, Reeder JC, and Rowe JA, A human complement receptor 1 polymorphism that reduces Plasmodium falciparum rosetting confers protection against severe malariaProc Natl Acad Sci U S AYear: 200410112727 31417514694201
75. Horata N,Kalambaheti T,Craig A,Khusmith S. Sequence variation of PfEMP1-DBLalpha in association with rosette formation in Plasmodium falciparum isolates causing severe and uncomplicated malariaMalar JYear: 20098184 322492819650937
76. Rogerson SJ,Beeson JG,Mhango CG,Dzinjalamala FK,Molyneux ME. Plasmodium falciparum rosette formation is uncommon in isolates from pregnant womenInfect ImmunYear: 20006813913 9714710603414
77. Chotivanich K,Udomsangpetch R,Suwanarusk R,Pukrittayakamee S,Wilairatana P,Beeson JG,Day NP,White NJ. Plasmodium vivax adherence to placental glycosaminoglycansPLoS ONEYear: 201274e34509 332847422529919
78. Carvalho BO,Lopes SC,Nogueira PA,Orlandi PP,Bargieri DY,Blanco YC,Mamoni R,Leite JA,Rodrigues MM,Soares IS,Oliveira TR,Wunderlich G,Lacerda MV,del Portillo HA,Araujo MO,Russell B,Suwanarusk R,Snounou G,Renia L,Costa FT. On the cytoadhesion of Plasmodium vivax-infected erythrocytesJ Infect DisYear: 2010202463847 20617923
79. Bouyou-Akotet MK,Adegnika AA,Agnandji ST,Ngou-Milama E,Kombila M,Kremsner PG,Mavoungou E. Cortisol and susceptibility to malaria during pregnancyMicrobes InfectYear: 2005711–12121723 16002311
80. Adebami OJ,Owa JA,Oyedeji GA,Oyelami OA,Omoniyi-Esan GO. Associations between placental and cord blood malaria infection and fetal malnutrition in an area of malaria holoendemicityAm J Trop Med HygYear: 20077722091317690388
81. McGready R,Davison BB,Stepniewska K,Cho T,Shee H,Brockman A,Udomsangpetch R,Looareesuwan S,White NJ,Meshnick SR,Nosten F. The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmissionAm J Trop Med HygYear: 200470439840715100454
82. Ismail MR,Ordi J,Menendez C,Ventura PJ,Aponte JJ,Kahigwa E,Hirt R,Cardesa A,Alonso PL. Placental pathology in malaria: a histological, immunohistochemical, and quantitative studyHum PatholYear: 20003118593 10665918
83. Tako EA,Zhou A,Lohoue J,Leke R,Taylor DW,Leke RF. Risk factors for placental malaria and its effect on pregnancy outcome in Yaounde, CameroonAm J Trop Med HygYear: 20057232364215772313
84. Suguitan AL Jr,Cadigan TJ,Nguyen TA,Zhou A,Leke RJ,Metenou S,Thuita L,Megnekou R,Fogako J,Leke RG,Taylor DW. Malaria-associated cytokine changes in the placenta of women with pre-term deliveries in Yaounde, CameroonAm J Trop Med HygYear: 20036965748114740871
85. Adam I,Elhassan EM,Haggaz AE,Ali AA,Adam GK. A perspective of the epidemiology of malaria and anaemia and their impact on maternal and perinatal outcomes in SudanJ Infect Dev CtriesYear: 201152837 21389586
86. Conroy AL,McDonald CR,Silver KL,Liles WC,Kain KC. Complement activation: a critical mediator of adverse fetal outcomes in placental malaria?Trends ParasitolYear: 20112772949 21493146
87. Umbers AJ,Boeuf P,Clapham C,Stanisic DI,Baiwog F,Mueller I,Siba P,King CL,Beeson JG,Glazier J,Rogerson SJ. Placental malaria-associated inflammation disturbs the insulin-like growth factor axis of fetal growth regulationJ Infect DisYear: 201120345619 307122421216864
88. WHOGuidelines for the treatment of malariaSecond editionYear: 2010Geneva, Switzerland132
89. Mayor A,Moro L,Aguilar R,Bardaj A,Cister P,Serra-Casas E,Sigaque B,Alonso PL,Ordi J,Menndez C. How Hidden Can Malaria Be in Pregnant Women? Diagnosis by Microscopy, Placental Histology, Polymerase Chain Reaction and Detection of Histidine-Rich Protein 2 in PlasmaClinical Infectious DiseasesYear: 2012541115611568 22447794
90. Mockenhaupt FP,Ulmen U,von Gaertner C,Bedu-Addo G,Bienzle U. Diagnosis of placental malariaJ Clin MicrobiolYear: 20024013068 12013111773140
91. VanderJagt TA,Ikeh EI,Ujah IO,Belmonte J,Glew RH,VanderJagt DJ. Comparison of the OptiMAL rapid test and microscopy for detection of malaria in pregnant women in NigeriaTrop Med Int HealthYear: 20051013941 15655012
92. Dondorp A,Nosten F,Stepniewska K,Day N,White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trialLancetYear: 2005366948771725 16125588
93. Leenstra T,Phillips-Howard PA,Kariuki SK,Hawley WA,Alaii JA,Rosen DH,Oloo AJ,Nahlen BL,Kager PA,ter Kuile FO. Permethrin-treated bed nets in the prevention of malaria and anemia in adolescent schoolgirls in western KenyaAm J Trop Med HygYear: 2003684 Suppl869312749490
94. ter Kuile FO,Terlouw DJ,Kariuki SK,Phillips-Howard PA,Mirel LB,Hawley WA,Friedman JF,Shi YP,Kolczak MS,Lal AA,Vulule JM,Nahlen BL. Impact of permethrin-treated bed nets on malaria, anemia, and growth in infants in an area of intense perennial malaria transmission in western KenyaAm J Trop Med HygYear: 2003684 Suppl687712749488
95. Jayasooriya S,Hislop A,Peng Y,Croom-Carter D,Jankey Y,Bell A,Dong T,Rowland-Jones S,Rickinson A,Walther M,Whittle H. Revisiting the effect of acute P. falciparum malaria on Epstein-Barr virus: host balance in the setting of reduced malaria endemicityPLoS ONEYear: 201272e31142 327558222347443
96. Phillips-Howard PA,Nahlen BL,Kolczak MS,Hightower AW,ter Kuile FO,Alaii JA,Gimnig JE,Arudo J,Vulule JM,Odhacha A,Kachur SP,Schoute E,Rosen DH,Sexton JD,Oloo AJ,Hawley WA. Efficacy of permethrin-treated bed nets in the prevention of mortality in young children in an area of high perennial malaria transmission in western KenyaAm J Trop Med HygYear: 2003684 Suppl23912749482
97. ter Kuile FO,Terlouw DJ,Phillips-Howard PA,Hawley WA,Friedman JF,Kariuki SK,Shi YP,Kolczak MS,Lal AA,Vulule JM,Nahlen BL. Reduction of malaria during pregnancy by permethrin-treated bed nets in an area of intense perennial malaria transmission in western KenyaAm J Trop Med HygYear: 2003684 Suppl506012749486
98. Njagi JK,Magnussen P,Estambale B,Ouma J,Mugo B. Prevention of anaemia in pregnancy using insecticide-treated bednets and sulfadoxine-pyrimethamine in a highly malarious area of Kenya: a randomized controlled trialTrans R Soc Trop Med HygYear: 200397327782 15228241
99. Browne EN,Maude GH,Binka FN. The impact of insecticide-treated bednets on malaria and anaemia in pregnancy in Kassena-Nankana district, Ghana: a randomized controlled trialTrop Med Int HealthYear: 20016966776 11555433
100. Diakite OS,Kayentao K,Traore BT,Djimde A,Traore B,Diallo M,Ongoiba A,Doumtabe D,Doumbo S,Traore MS,Dara A,Guindo O,Karim DM,Coulibaly S,Bougoudogo F,Ter Kuile FO,Danis M,Doumbo OK. Superiority of 3 over 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine for the prevention of malaria during pregnancy in mali: a randomized controlled trialClin Infect DisYear: 201153321523 21765069
101. Menendez C,Bardaji A,Sigauque B,Romagosa C,Sanz S,Serra-Casas E,Macete E,Berenguera A,David C,Dobano C,Naniche D,Mayor A,Ordi J,Mandomando I,Aponte JJ,Mabunda S,Alonso PL. A randomized placebo-controlled trial of intermittent preventive treatment in pregnant women in the context of insecticide treated nets delivered through the antenatal clinicPLoS ONEYear: 200834e193418398460
102. Asa OO,Onayade AA,Fatusi AO,Ijadunola KT,Abiona TC. Efficacy of intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine in preventing anaemia in pregnancy among Nigerian womenMatern Child Health JYear: 20081266928 18274885
103. Tukur IU,Thacher TD,Sagay AS,Madaki JK. A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian womenAm J Trop Med HygYear: 200776610192317556604
104. Challis K,Osman NB,Cotiro M,Nordahl G,Dgedge M,Bergstrom S. Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern MozambiqueTrop Med Int HealthYear: 2004910106673 15482398
105. Bertin G,Briand V,Bonaventure D,Carrieu A,Massougbodji A,Cot M,Deloron P. Molecular markers of resistance to sulphadoxine-pyrimethamine during intermittent preventive treatment of pregnant women in BeninMalar JYear: 201110196 319990321767415
106. ter Kuile FO,van Eijk AM,Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy: a systematic reviewJAMAYear: 200729723260316 17579229
107. Clerk CA,Bruce J,Affipunguh PK,Mensah N,Hodgson A,Greenwood B,Chandramohan D. A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in GhanaJ Infect DisYear: 20081988120211 18752443
108. Briand V,Denoeud L,Massougbodji A,Cot M. Efficacy of intermittent preventive treatment versus chloroquine prophylaxis to prevent malaria during pregnancy in BeninJ Infect DisYear: 20081984594601 18598190
109. Briand V,Bottero J,Noel H,Masse V,Cordel H,Guerra J,Kossou H,Fayomi B,Ayemonna P,Fievet N,Massougbodji A,Cot M. Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquineJ Infect DisYear: 200920069911001 19656069
110. Ndyomugyenyi R,Clarke SE,Hutchison CL,Hansen KS,Magnussen P. Efficacy of malaria prevention during pregnancy in an area of low and unstable transmission: an individually-randomised placebo-controlled trial using intermittent preventive treatment and insecticide-treated nets in the Kabale Highlands, southwestern UgandaTrans R Soc Trop Med HygYear: 20111051160716 21962292
111. Hviid L. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine developmentHum VaccinYear: 201061849 19823032
112. Menendez C,Alonso P. Universitat de BGuidelines and considerations for testing malaria vaccines in pregnant womenHum VaccinYear: 20106121619946207
113. Crompton PD,Pierce SK,Miller LH. Advances and challenges in malaria vaccine developmentJ Clin InvestYear: 201012012416878 299434221123952
114. Duffy PE,Fried M. Antibodies that inhibit Plasmodium falciparum adhesion to chondroitin sulfate A are associated with increased birth weight and the gestational age of newbornsInfect ImmunYear: 2003711166203 21954614573685
115. Magistrado PA,Minja D,Doritchamou J,Ndam NT,John D,Schmiegelow C,Massougbodji A,Dahlback M,Ditlev SB,Pinto VV,Resende M,Lusingu J,Theander TG,Salanti A,Nielsen MA. High efficacy of anti DBL4varepsilon-VAR2CSA antibodies in inhibition of CSA-binding Plasmodium falciparum-infected erythrocytes from pregnant womenVaccineYear: 201129343743 21075162
116. Duffy PE,Fried M. Pregnancy malaria: cryptic disease, apparent solutionMem Inst Oswaldo CruzYear: 2011106Suppl 1649 21881758
117. Hviid L. The case for PfEMP1-based vaccines to protect pregnant women against Plasmodium falciparum malariaExpert Rev VaccinesYear: 20111010140514 21988306
118. McGready R,Cho T,Keo NK,Thwai KL,Villegas L,Looareesuwan S,White NJ,Nosten F. Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparumClin Infect DisYear: 20013312200916 11712093
119. Manyando C,Mkandawire R,Puma L,Sinkala M,Mpabalwani E,Njunju E,Gomes M,Ribeiro I,Walter V,Virtanen M,Schlienger R,Cousin M,Chipimo M,Sullivan FM. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in ZambiaMalar JYear: 20109249 294433920809964
120. Deen JL,von Seidlein L,Pinder M,Walraven GE,Greenwood BM. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancyTrans R Soc Trop Med HygYear: 20019544248 11579889
121. Adam I,Elhassan EM,Omer EM,Abdulla MA,Mahgoub HM,Adam GK. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese womenAnn Trop Med ParasitolYear: 2009103320510 19341535
122. Tagbor H,Bruce J,Browne E,Randal A,Greenwood B,Chandramohan D. Efficacy, safety, and tolerability of amodiaquine plus sulphadoxine-pyrimethamine used alone or in combination for malaria treatment in pregnancy: a randomised trialLancetYear: 20063689544134956 17046467
123. McGready R,Ashley EA,Moo E,Cho T,Barends M,Hutagalung R,Looareesuwan S,White NJ,Nosten F. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancyJ Infect DisYear: 2005192584653 16088834
124. McGready R,Cho T,Samuel,Villegas L,Brockman A,van Vugt M,Looareesuwan S,White NJ,Nosten F. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancyTrans R Soc Trop Med HygYear: 20019566516 11816439
125. Mutabingwa TK,Muze K,Ord R,Briceno M,Greenwood BM,Drakeley C,Whitty CJ. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in TanzaniaPLoS ONEYear: 200944e5138 266242319352498
126. McGready R,Brockman A,Cho T,Cho D,van Vugt M,Luxemburger C,Chongsuphajaisiddhi T,White NJ,Nosten F. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancyTrans R Soc Trop Med HygYear: 200094668993 11198658
127. Kalilani L,Mofolo I,Chaponda M,Rogerson SJ,Alker AP,Kwiek JJ,Meshnick SR. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant womenPLoS ONEYear: 2007211e1166 204866118000538
128. Tarning J,Kloprogge F,Piola P,Dhorda M,Muwanga S,Turyakira E,Nuengchamnong N,Nosten F,Day N,White N,Guerin P,Lindegardh N. Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in UgandaMalaria JournalYear: 2012111293 350216622913677
129. Tarning J,McGready R,Lindegardh N,Ashley EA,Pimanpanarak M,Kamanikom B,Annerberg A,Day NP,Stepniewska K,Singhasivanon P,White NJ,Nosten F. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malariaAntimicrob Agents ChemotherYear: 2009539383746 273788719564366
130. Schlagenhauf P,Blumentals WA,Suter P,Regep L,Vital-Durand G,Schaerer MT,Boutros MS,Rhein H-G,Adamcova M. Pregnancy and Fetal Outcomes After Exposure to Mefloquine in the Pre- and Periconception Period and During PregnancyClinical Infectious DiseasesYear: 2012 334895122495078
131. Rijken MJ,McGready R,Jullien V,Tarning J,Lindegardh N,Phyo AP,Win AK,Hsi P,Cammas M,Singhasivanon P,White NJ,Nosten F. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malariaAntimicrob Agents ChemotherYear: 2011559433842 316532021709098
132. McGready R,White NJ,Nosten F. Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic reviewBJOGYear: 2011118212335 21159117
133. Tarning J,Rijken MJ,McGready R,Phyo AP,Hanpithakpong W,Day NP,White NJ,Nosten F,Lindegardh N. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malariaAntimicrob Agents ChemotherYear: 201256419972007 331833222252822
134. McGready R,Stepniewska K,Ward SA,Cho T,Gilveray G,Looareesuwan S,White NJ,Nosten F. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malariaEur J Clin PharmacolYear: 200662536771 16552504
135. Tarning J,Chotsiri P,Jullien V,Rijken MJ,Bergstrand M,Cammas M,McGready R,Singhasivanon P,Day NP,White NJ,Nosten F,Lindegardh N. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancyAntimicrob Agents ChemotherYear: 2012 348662022926572
136. Piola P,Nabasumba C,Turyakira E,Dhorda M,Lindegardh N,Nyehangane D,Snounou G,Ashley EA,McGready R,Nosten F,Guerin PJ. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trialLancet Infect DisYear: 201010117629 20932805
137. Kaye DK,Nshemerirwe R,Mutyaba TS,Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone in treatment of uncomplicated malaria in pregnancy in Mulago hospital, UgandaJ Infect Dev CtriesYear: 2008221359 19738339
138. McGready R,Tan SO,Ashley EA,Pimanpanarak M,Viladpai-Nguen J,Phaiphun L,Wustefeld K,Barends M,Laochan N,Keereecharoen L,Lindegardh N,Singhasivanon P,White NJ,Nosten F. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancyPLoS MedYear: 2008512e253 260590019265453
139. McGready R,Stepniewska K,Lindegardh N,Ashley EA,La Y,Singhasivanon P,White NJ,Nosten F. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malariaEur J Clin PharmacolYear: 20066212102131 17053895
140. Rijken MJ,McGready R,Phyo AP,Lindegardh N,Tarning J,Laochan N,Than HH,Mu O,Win AK,Singhasivanon P,White N,Nosten F. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malariaAntimicrob Agents ChemotherYear: 2011551255006 323275521947392
141. Poespoprodjo JR,Fobia W,Kenangalem E,Hasanuddin A,Sugiarto P,Tjitra E,Anstey NM,Price RN. Highly effective therapy for maternal malaria associated with a lower risk of vertical transmissionJ Infect DisYear: 20112041016139 319218821908728
142. McGready R,Keo NK,Villegas L,White NJ,Looareesuwan S,Nosten F. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary reportTrans R Soc Trop Med HygYear: 20039755924 15307434
143. McGready R,Stepniewska K,Edstein MD,Cho T,Gilveray G,Looareesuwan S,White NJ,Nosten F. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malariaEur J Clin PharmacolYear: 200359754552 12955371
144. Kabanywanyi AM,Macarthur JR,Stolk WA,Habbema JD,Mshinda H,Bloland PB,Abdulla S,Kachur SP. Malaria in pregnant women in an area with sustained high coverage of insecticide-treated bed netsMalar JYear: 20087133 250004018644118
145. Campos PA,Valente B,Campos RB,Goncalves L,Rosario VE,Varandas L,Silveira H. Plasmodium falciparum infection in pregnant women attending antenatal care in Luanda, AngolaRev Soc Bras Med TropYear: 201245336974 22760138
146. Martinez-Espinosa FE,Daniel-Ribeiro CT,Alecrim WD. Malaria during pregnancy in a reference centre from the Brazilian Amazon: unexpected increase in the frequency of Plasmodium falciparum infectionsMem Inst Oswaldo CruzYear: 20049911921 15057341
147. Karunajeewa HA,Salman S,Mueller I,Baiwog F,Gomorrai S,Law I,Page-Sharp M,Rogerson S,Siba P,Ilett KF,Davis TM. Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancyAntimicrob Agents ChemotherYear: 2010543118692 282596720086162
148. Nyunt MM,Adam I,Kayentao K,van Dijk J,Thuma P,Mauff K,Little F,Cassam Y,Guirou E,Traore B,Doumbo O,Sullivan D,Smith P,Barnes KI. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancyClin Pharmacol TherYear: 201087222634 350497319776738
149. McGready R,Thwai KL,Cho T,Samuel,Looareesuwan S,White NJ,Nosten F. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancyTrans R Soc Trop Med HygYear: 20029621804 12055810

Article Categories:
  • Review Articles

Previous Document:  Role of haematological parameters as an indicator of acute malarial infection in uttarakhand state o...
Next Document:  Russeting in apple and pear: a plastic periderm replaces a stiff cuticle.